In Vivo Target Gene Activation via CRISPR/Cas9-Mediated Trans-epigenetic Modulation

[1]  E A Barnard,et al.  The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. , 1989, Science.

[2]  K. Davies,et al.  Amelioration of the dystrophic phenotype of mdx mice using a truncated utrophin transgene , 1996, Nature.

[3]  K. Davies,et al.  Skeletal muscle-specific expression of a utrophin transgene rescues utrophin-dystrophin deficient mice , 1998, Nature Genetics.

[4]  K. Davies,et al.  A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  I. Barshack,et al.  Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates streptozotocin-induced hyperglycemia , 2000, Nature Medicine.

[6]  Animesh Nandi,et al.  Suppression of Aging in Mice by the Hormone Klotho , 2005, Science.

[7]  Lung-Ji Chang,et al.  Reprogramming liver-stem WB cells into functional insulin-producing cells by persistent expression of Pdx1- and Pdx1-VP16 mediated by lentiviral vectors , 2006, Laboratory Investigation.

[8]  A. McMahon,et al.  Six2 defines and regulates a multipotent self-renewing nephron progenitor population throughout mammalian kidney development. , 2008, Cell stem cell.

[9]  J. Mendell,et al.  Long-term enhancement of skeletal muscle mass and strength by single gene administration of myostatin inhibitors , 2008, Proceedings of the National Academy of Sciences.

[10]  J. Rabinowitz,et al.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[11]  H. Aburatani,et al.  Genome-Wide Profiling of the Core Clock Protein BMAL1 Targets Reveals a Strict Relationship with Metabolism , 2010, Neuroscience Research.

[12]  Y. Lau,et al.  An essential protective role of IL-10 in the immunological mechanism underlying resistance vs susceptibility to lupus induction by dendritic cells and dying cells , 2011, Rheumatology.

[13]  J. Doudna,et al.  A Programmable Dual-RNA–Guided DNA Endonuclease in Adaptive Bacterial Immunity , 2012, Science.

[14]  Neville E Sanjana,et al.  A transcription activator-like effector toolbox for genome engineering , 2012, Nature Protocols.

[15]  Pernette J. Verschure,et al.  Epigenetic Editing: targeted rewriting of epigenetic marks to modulate expression of selected target genes , 2012, Nucleic acids research.

[16]  Christopher M. Vockley,et al.  RNA-guided gene activation by CRISPR-Cas9-based transcription factors , 2013, Nature Methods.

[17]  Luke A. Gilbert,et al.  CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes , 2013, Cell.

[18]  Prashant Mali,et al.  Orthogonal Cas9 Proteins for RNA-Guided Gene Regulation and Editing , 2013, Nature Methods.

[19]  N. Chen,et al.  Interleukin-10 deficiency aggravates kidney inflammation and fibrosis in the unilateral ureteral obstruction mouse model , 2013, Laboratory Investigation.

[20]  Luke A. Gilbert,et al.  Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression , 2013, Cell.

[21]  R. Maehr,et al.  Cas9 effector-mediated regulation of transcription and differentiation in human pluripotent stem cells , 2014, Development.

[22]  K. Foust,et al.  Intravenous injections in neonatal mice. , 2014, Journal of visualized experiments : JoVE.

[23]  Robert Langer,et al.  CRISPR-Cas9 Knockin Mice for Genome Editing and Cancer Modeling , 2014, Cell.

[24]  A. Czechanski,et al.  Derivation and characterization of mouse embryonic stem cells from permissive and nonpermissive strains , 2014, Nature Protocols.

[25]  Sarah A Heerboth,et al.  Use of Epigenetic Drugs in Disease: An Overview , 2014, Genetics & epigenetics.

[26]  Max A. Horlbeck,et al.  Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation , 2014, Cell.

[27]  Stacy D. Grunke,et al.  Intracerebroventricular viral injection of the neonatal mouse brain for persistent and widespread neuronal transduction. , 2014, Journal of Visualized Experiments.

[28]  O. Moe,et al.  Klotho has dual protective effects on cisplatin-induced acute kidney injury , 2013, Kidney international.

[29]  Ronald D. Vale,et al.  A Protein-Tagging System for Signal Amplification in Gene Expression and Fluorescence Imaging , 2014, Cell.

[30]  Lei S. Qi,et al.  The New State of the Art: Cas9 for Gene Activation and Repression , 2015, Molecular and Cellular Biology.

[31]  Philip Hunter,et al.  The second coming of epigenetic drugs , 2015, EMBO reports.

[32]  G. Church,et al.  Cas9 gRNA engineering for genome editing, activation and repression , 2015, Nature Methods.

[33]  W. Kułak,et al.  Duchenne muscular dystrophy: current cell therapies , 2015, Therapeutic advances in neurological disorders.

[34]  G. Remuzzi,et al.  Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury , 2015, Scientific Reports.

[35]  Feng Zhang,et al.  In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9 , 2014, Nature Biotechnology.

[36]  M. Ravichandran,et al.  Synthetic epigenetics—towards intelligent control of epigenetic states and cell identity , 2015, Clinical Epigenetics.

[37]  N. Perrimon,et al.  Highly-efficient Cas9-mediated transcriptional programming , 2015, Nature Methods.

[38]  Keiichiro Suzuki,et al.  Use of the CRISPR/Cas9 system as an intracellular defense against HIV-1 infection in human cells , 2015, Nature Communications.

[39]  Alexandro E. Trevino,et al.  Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex , 2014, Nature.

[40]  Philip Hunter Freelance journalist.  The second coming of epigenetic drugs , 2015 .

[41]  Feng Zhang,et al.  Orthogonal gene knock out and activation with a catalytically active Cas9 nuclease , 2015, Nature Biotechnology.

[42]  James J. Collins,et al.  Comparative Analysis of Cas9 Activators Across Multiple Species , 2016, Nature Methods.

[43]  N. Khanlou,et al.  Klotho gene silencing promotes pathology in the mdx mouse model of Duchenne muscular dystrophy. , 2016, Human molecular genetics.

[44]  George Church,et al.  Next stop for the CRISPR revolution: RNA‐guided epigenetic regulators , 2016, The FEBS journal.

[45]  Dongsheng Duan,et al.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy , 2016, Science.

[46]  K. Davies,et al.  Correlation of Utrophin Levels with the Dystrophin Protein Complex and Muscle Fibre Regeneration in Duchenne and Becker Muscular Dystrophy Muscle Biopsies , 2016, PloS one.

[47]  I. Pastan,et al.  3D Culture Supports Long-Term Expansion of Mouse and Human Nephrogenic Progenitors. , 2016, Cell stem cell.

[48]  John M. Shelton,et al.  Postnatal genome editing partially restores dystrophin expression in a mouse model of muscular dystrophy , 2016, Science.

[49]  Isaac B. Hilton,et al.  Editing the epigenome: technologies for programmable transcription and epigenetic modulation , 2016, Nature Methods.

[50]  Prashant Mali,et al.  A multifunctional AAV–CRISPR–Cas9 and its host response , 2016, Nature Methods.

[51]  George M. Church,et al.  In vivo gene editing in dystrophic mouse muscle and muscle stem cells , 2016, Science.

[52]  Lucia Altucci,et al.  Epigenetic drugs: from chemistry via biology to medicine and back , 2016, Clinical Epigenetics.

[53]  Edward M. Callaway,et al.  In vivo genome editing via CRISPR/Cas9 mediated homology-independent targeted integration , 2016, Nature.

[54]  A. Bassuk,et al.  Unexpected mutations after CRISPR–Cas9 editing in vivo , 2017, Nature Methods.

[55]  Lei S. Qi,et al.  Repurposing CRISPR System for Transcriptional Activation. , 2017, Advances in experimental medicine and biology.

[56]  I. Sancho-Martinez,et al.  Integration of CpG-free DNA induces de novo methylation of CpG islands in pluripotent stem cells , 2017, Science.

[57]  A. Ashworth,et al.  Marked for death: targeting epigenetic changes in cancer , 2017, Nature Reviews Drug Discovery.

[58]  David R. Liu,et al.  CRISPR-Based Technologies for the Manipulation of Eukaryotic Genomes , 2017, Cell.